97 related articles for article (PubMed ID: 23063567)
1. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period.
Mariño Z; Crespo G; D'Amato M; Brambilla N; Giacovelli G; Rovati L; Costa J; Navasa M; Forns X
J Hepatol; 2013 Mar; 58(3):415-20. PubMed ID: 23063567
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial.
Rendina M; D'Amato M; Castellaneta A; Castellaneta NM; Brambilla N; Giacovelli G; Rovati L; Rizzi SF; Zappimbulso M; Bringiotti RS; Di Leo A
Transpl Int; 2014 Jul; 27(7):696-704. PubMed ID: 24673819
[TBL] [Abstract][Full Text] [Related]
3. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.
Bárcena R; Moreno A; Rodríguez-Gandía MA; Albillos A; Arocena C; Blesa C; García-Hoz F; Graus J; Nuño J; López-Hervás P; Gajate L; Martínez A; Bermejo T; Mateos ML; Del Campo S;
J Hepatol; 2013 Mar; 58(3):421-6. PubMed ID: 23073223
[TBL] [Abstract][Full Text] [Related]
4. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
Biermer M; Schlosser B; Fülöp B; van Bömmel F; Brodzinski A; Heyne R; Keller K; Sarrazin C; Berg T
J Viral Hepat; 2012 Aug; 19(8):547-53. PubMed ID: 22762138
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
DebRoy S; Hiraga N; Imamura M; Hayes CN; Akamatsu S; Canini L; Perelson AS; Pohl RT; Persiani S; Uprichard SL; Tateno C; Dahari H; Chayama K
J Viral Hepat; 2016 Sep; 23(9):708-17. PubMed ID: 27272497
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
Burra P; Senzolo M; Masier A; Prestele H; Jones R; Samuel D; Villamil F
Dig Liver Dis; 2009 May; 41(5):350-6. PubMed ID: 19046932
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
Hotho DM; de Bruijne J; O'Farrell AM; Boyea T; Li J; Bracken M; Li X; Campbell D; Guler HP; Weegink CJ; Schinkel J; Molenkamp R; van de Wetering de Rooij J; van Vliet A; Janssen HL; de Knegt RJ; Reesink HW
Antivir Ther; 2012; 17(2):365-75. PubMed ID: 22293533
[TBL] [Abstract][Full Text] [Related]
8. Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
Merli M; Giannelli V; Gentili F; Giusto M; Simmaco M; Lionetto L; Corradini SG; Biliotti E; Attili AF; Rossi M; Taliani G
Antivir Ther; 2011; 16(6):879-85. PubMed ID: 21900720
[TBL] [Abstract][Full Text] [Related]
9. Rescue therapy with intravenous silibinin in liver transplant recipients with recurrent HCV hepatitis - two case reports.
Socha Ł; Karpińska E; Jurczyk K; Laurans Ł; Bander D; Lachtara M; Wawrzynowicz-Syczewska M
Ann Transplant; 2014 Apr; 19():161-4. PubMed ID: 24714452
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients.
Duclos-Vallée JC; Vittecoq D; Teicher E; Feray C; Roque-Afonso AM; Lombès A; Jardel C; Gigou M; Dussaix E; Sebagh M; Guettier C; Azoulay D; Adam R; Ichaï P; Saliba F; Roche B; Castaing D; Bismuth H; Samuel D
J Hepatol; 2005 Mar; 42(3):341-9. PubMed ID: 15710216
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
[TBL] [Abstract][Full Text] [Related]
12. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
13. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation.
Sreekumar R; Gonzalez-Koch A; Maor-Kendler Y; Batts K; Moreno-Luna L; Poterucha J; Burgart L; Wiesner R; Kremers W; Rosen C; Charlton MR
Hepatology; 2000 Nov; 32(5):1125-30. PubMed ID: 11050065
[TBL] [Abstract][Full Text] [Related]
14. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence.
Ghabril M; Dickson RC; Krishna M; Machicao V; Aranda-Michel J; Bonatti H; Nguyen JH
Liver Transpl; 2011 Jun; 17(6):685-94. PubMed ID: 21618689
[TBL] [Abstract][Full Text] [Related]
15. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients.
Khettry U; Huang WY; Simpson MA; Pomfret EA; Pomposelli JJ; Lewis WD; Jenkins RL; Gordon FD
Hum Pathol; 2007 Mar; 38(3):443-52. PubMed ID: 17188331
[TBL] [Abstract][Full Text] [Related]
16. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
[TBL] [Abstract][Full Text] [Related]
17. Flexible and individualized treatment to achieve sustained viral response for recurrent hepatitis C in liver transplant recipients.
Lee WC; Wu TJ; Chou HS; Lee CF; Chan KM; Cheng SS
J Viral Hepat; 2010 Nov; 17(11):770-7. PubMed ID: 20337926
[TBL] [Abstract][Full Text] [Related]
18. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.
Yilmaz N; Shiffman ML; Stravitz RT; Sterling RK; Luketic VA; Sanyal AJ; Mills AS; Contos MJ; Coterell A; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2007 Jul; 13(7):975-83. PubMed ID: 17600360
[TBL] [Abstract][Full Text] [Related]
19. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C.
Ciccorossi P; Maina AM; Oliveri F; Petruccelli S; Leandro G; Colombatto P; Moriconi F; Mosca F; Filipponi F; Bonino F; Brunetto MR
Liver Int; 2007 Jun; 27(5):612-9. PubMed ID: 17498245
[TBL] [Abstract][Full Text] [Related]
20. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation.
Di Benedetto F; Di Sandro S; De Ruvo N; Montalti R; Ballarin R; Guerrini GP; Spaggiari M; Guaraldi G; Gerunda G
Transplantation; 2010 Mar; 89(6):733-8. PubMed ID: 20048692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
